Merck(NYSE) MRK

Merck & Co., Inc. makes medicines and vaccines for people and animals. These products help doctors treat cancer, infections, and heart problems. It also helps farmers and pet owners keep their animals healthy.

Products for People and Animals

• Oncology Care: Cancer treatments including the immunotherapy drug Keytruda; pharmaceutical segment sales reached $11.6 billion in the second quarter of 2026.
• Human Vaccines: Preventive shots for diseases such as pneumonia and Human Papillomavirus (HPV); combined HPV vaccine sales were $1.2 billion in the second quarter of 2026.
• Animal Health: Veterinary medicines and digital monitoring tools for livestock and pets; segment sales reached $1.8 billion in the second quarter of 2026.
• Cardiometabolic Therapies: Treatments for heart and lung conditions including pulmonary arterial hypertension (high blood pressure in the lungs); Winrevair sales rose 75% to $588 million in the second quarter of 2026.

Growth through Strategic Acquisitions

• Acquired Cidara Therapeutics for $9.2 billion in January 2026 to obtain a long-acting antiviral candidate for influenza prevention.
• Purchased Terns Pharmaceuticals for $6.8 billion in May 2026 to add an oral leukemia treatment candidate to the oncology pipeline.
• Acquired TARGAN for approximately $650 million in July 2026 to incorporate automated biodevice technology for poultry health operations.
• Entered a three-year agreement with the U.S. government in December 2025 to offer direct-to-patient affordable pricing for certain diabetes medicines.

Diversified Science and Research

Merck operates a dedicated division known as Merck Research Laboratories that focuses on human health drug development. The company maintains balanced operations by pairing its human pharmaceutical business with a segment focused on veterinary medications and digital identification products for livestock.

Financial Performance in 2026

• Worldwide sales were $32.9 billion in the first six months of 2026, up 5% year over year.
• The company reported a GAAP net loss of $4.2 billion in the first six months of 2026, compared to an income of $10.9 billion in the same period of 2025.
• Research and development expenses reached $22.3 billion in the first six months of 2026, largely due to $14.7 billion in charges for business acquisitions.
• Cash provided by operating activities was $9.3 billion in the first six months of 2026, up from $5.8 billion in the first six months of 2025.

Company Evolution and Focus

Merck has transitioned its focus toward high-growth areas like oncology and rare respiratory diseases while maintaining a significant presence in animal health. Strategic acquisitions and internal research continue to reshape its product pipeline as older medicines face generic competition and pricing pressure.